Despite its therapeutic potential, targeting PKC is challenging due to its complex regulation and the presence of multiple isoforms with distinct and sometimes opposing functions. Isoform-specific effects need to be carefully considered to avoid unwanted side effects. Additionally, the development of selective PKC inhibitors is complicated by the need for precise modulation of its activity without affecting other kinases.
